Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ('Tiziana” or the 'Company”), a biotechnology company developing breakthrough immunomodulation therapies, today announced that its Phase 2 clinical trial ...
The interdisciplinary curriculum helps future physicians develop insights and perspectives that set them apart in medical ...
Opinion
3dOpinion
This CEO Just Sold His Company for $21 Billion. It Wouldn’t Have Happened Without Federally Funded Research
When companies do solve that puzzle, the rewards can be huge: As Modern CEO went to press, Exact Sciences announced it was selling to Abbott in a deal valued at $21 billion.
Abbott's $23B Exact Sciences deal adds short-term risk and earnings dilution. Click here to read what this means for ABT ...
Australians have always been fiercely proud of the CSIRO - and rightly so.
Researchers at the Nano Life Science Institute (WPI-NanoLSI), Kanazawa University, have developed a breakthrough method for quantitative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback